News
AGMB
10.66
+1.81%
0.19
Weekly Report: what happened at AGMB last week (0406-0410)?
Weekly Report · 2d ago
Weekly Report: what happened at AGMB last week (0330-0403)?
Weekly Report · 04/06 10:47
Weekly Report: what happened at AGMB last week (0323-0327)?
Weekly Report · 03/30 10:48
Agomab receives U.S. patent for AGMB-447
TipRanks · 03/26 11:31
AGOMAB RECEIVES U.S. PATENT FOR AGMB-447, ITS INHALED LUNG-RESTRICTED SMALL MOLECULE INHIBITOR OF ALK5 IN DEVELOPMENT FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Reuters · 03/26 11:02
Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041
Reuters · 03/26 11:01
Weekly Report: what happened at AGMB last week (0316-0320)?
Weekly Report · 03/23 10:43
Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement
Reuters · 03/18 20:03
Agomab Therapeutics NV CFO Kemula Pierre Thadee Victor files Form 3 initial beneficial ownership statement
Reuters · 03/18 20:03
Agomab Therapeutics NV CEO and Director Tim Jasper Knotnerus Files Initial Beneficial Ownership Statement
Reuters · 03/18 20:03
Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement
Reuters · 03/18 20:02
Agomab Therapeutics NV director Colin Michael Bond files Form 3 initial beneficial ownership statement
Reuters · 03/18 20:02
Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel
Reuters · 03/18 20:02
Agomab Therapeutics NV files Form 3 as Chief Business Officer Paul Henryk van der Horst reports beneficial ownership
Reuters · 03/18 20:02
Agomab Therapeutics NV files Form 3 beneficial ownership statement for Chief Development Officer Andrea Saez Borderias
Reuters · 03/18 20:02
Agomab Therapeutics NV files Form 3 beneficial ownership statement for General Counsel Ellen Lefever
Reuters · 03/18 20:02
Morgan Stanley Sticks to Its Buy Rating for AgomAb Therapeutics NV ADR (AGMB)
TipRanks · 03/16 13:16
Weekly Report: what happened at AGMB last week (0309-0313)?
Weekly Report · 03/16 10:42
Morgan Stanley Sticks to Their Buy Rating for AgomAb Therapeutics NV ADR (AGMB)
TipRanks · 03/10 10:36
Weekly Report: what happened at AGMB last week (0302-0306)?
Weekly Report · 03/09 10:42
More
Webull provides a variety of real-time AGMB stock news. You can receive the latest news about AgomAb Therapeutics NV through multiple platforms. This information may help you make smarter investment decisions.
About AGMB
Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.